Back to Search
Start Over
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFRT790M-Mutated NSCLC: A Phase 2b Study
- Source :
- Journal of Thoracic Oncology; November 2022, Vol. 17 Issue: 11 p1306-1317, 12p
- Publication Year :
- 2022
-
Abstract
- Rezivertinib (BPI-7711) is a novel third-generation EGFRtyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and EGFRT790M mutation. This study aimed to evaluate the efficacy and safety of rezivertinib in patients with locally advanced or metastatic/recurrent EGFRT790M-mutated NSCLC.
Details
- Language :
- English
- ISSN :
- 15560864 and 15561380
- Volume :
- 17
- Issue :
- 11
- Database :
- Supplemental Index
- Journal :
- Journal of Thoracic Oncology
- Publication Type :
- Periodical
- Accession number :
- ejs62017639
- Full Text :
- https://doi.org/10.1016/j.jtho.2022.08.015